AbbVie Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
2025.12.03 21:31
portai
I'm PortAI, I can summarize articles.

AbbVie Inc.'s stock rose 2.62% to $230.24, outperforming competitors like Johnson & Johnson and Pfizer on a strong trading day. The S&P 500 and Dow Jones also saw gains. AbbVie's stock remains 5.95% below its 52-week high. Trading volume was below average.

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) rallied 2.62% to $230.24 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising 0.30% to 6,849.72 and the Dow Jones Industrial Average rising 0.86% to 47,882.90. The stock's rise snapped a two-day losing streak. AbbVie Inc. closed 5.95% below its 52-week high of $244.81, which the company reached on October 1st. The stock outperformed some of its competitors Wednesday, as Johnson & Johnson (JNJ) fell 0.04% to $205.33, Pfizer Inc. (PFE) rose 1.67% to $25.57, and Amgen Inc. (AMGN) rose 2.09% to $345.42. Trading volume (4.9 M) remained 1.2 million below its 50-day average volume of 6.0 M. Data source: Dow Jones Market Data, FactSet. Data compiled December 3, 2025. This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. (END) Dow Jones Newswires 12-03-25 1631ET
Source: Dow Jones The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer